A Two-part, Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile of Single Ascending Doses of SAR441121 Including a Pilot Food Evaluation (TDU15302) and its Antimalarial Activity against Plasmodium falciparum Blood Stage Infection (PDY15303) in Healthy Male Subjects
Latest Information Update: 05 Nov 2018
At a glance
- Drugs SAR 441121 (Primary)
- Indications Malaria
- Focus Adverse reactions
- Sponsors Sanofi
- 05 Nov 2018 New trial record